Open main menu

Psychiatrienet β

Trazodone-clomipramine

Revision as of 14:53, 2 November 2015 by Anoek (talk | contribs)
Trazodone
Type Antidepressant
Group other
links
Medscape Trazodone
PubChem 5533
PubMed Trazodone
Kompas (Dutch) Trazodone
Wikipedia Trazodone
Clomipramine
Type Antidepressant
Group TCA
links
ATC-code N06AA04
Medscape Clomipramine
PubChem 2801
PubMed Clomipramine
Kompas (Dutch) Clomipramine
Wikipedia Clomipramine

Switch medication from trazodone to clomipramine.[1] [2]

Nietinrijdenbord.png Stop trazodone
  • Before day 1: gradually reduce dosage of trazodone to a maximum of 150-200 mg/day, when this dosage is > 150 mg/day.
  • Day 1: reduce dosage of trazodone to 75-100 mg/day.
  • Day 8: stop administration of trazodone.
Eenrichtingbord.png Start clomipramine

No wash-out period is needed.

  • Day 8: start administration of clomipramine in a dosage of 50 mg/day.
  • Day 15: increase dosage of clomipramine to 75 mg/day.
  • Start low, go slow.
Infobord.png More information
  • Occurrence of the serotonin syndrome is theoretically possible, so care is needed.
  • The content of trazodone in the tablet, for example 100 mg or 150 mg, determines which exact doses are given.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
  • This switch is currently being reviewed.